SS-31 (Elamipretide): What This New FDA Approval Means and How TBTotal.Health Uses It for Mitochondrial Support

SS-31, also known as Elamipretide or Forzinity, has become one of the most talked-about peptides in the longevity and mitochondrial-health space. It is the first therapy of its kind to receive FDA approval for a mitochondrial disorder, and it represents a major step forward for the field of cellular energy and aging.

At TBTotal.Health, we closely follow advancements in longevity medicine. Based on current evidence and patient interest, we offer SS-31 off-label for mitochondrial support and longevity-focused care. Patients can receive a telemedicine consultation and, when appropriate, a prescription through our secure platform.

Here is a clear and approachable explanation of what SS-31 is, how it works, and what its approval means for the broader field of wellness and aging.

What Is SS-31?

SS-31 is a small peptide that supports mitochondrial function. Mitochondria are the structures inside your cells responsible for producing energy. When they function well, you experience better energy, better physical performance, improved resilience, and healthier aging. When they decline, fatigue, inflammation, brain fog, and slower recovery become more common.

SS-31 binds to a mitochondrial membrane lipid called cardiolipin. This helps mitochondria produce energy more efficiently, handle stress more effectively, and repair cellular damage.

In simple terms, SS-31 helps support your cellular energy systems.

Why the FDA Approval Matters

In September 2025, the FDA approved SS-31 (brand name Forzinity) for Barth syndrome, a rare genetic mitochondrial disorder. This is the first therapy ever approved that directly targets mitochondrial structure and function.

This approval validates a long-standing idea: improving mitochondrial function can improve human health.

It also opens the door for expanded research into other conditions where mitochondrial dysfunction plays a role, including aging, fatigue, metabolic disorders, and cognitive decline.

How TBTotal.Health Uses SS-31

Although SS-31 is FDA-approved only for Barth syndrome, licensed providers may prescribe it off-label when clinically appropriate. At TBTotal.Health, we prescribe SS-31 off-label for patients seeking support for:

Mitochondrial health
Cellular resilience
Longevity optimization
Energy support
Recovery and stress tolerance

Patients can meet with a TBTotal.Health provider through telemedicine to review symptoms, goals, and medical history before receiving a prescription.

Our approach is transparent, evidence-informed, and focused on safety. We explain what is known, what is emerging, and what remains unproven.

Early Research: What SS-31 Might Help With

Although its approved indication is narrow, early studies in animals and small human trials suggest potential benefits such as:

Improved mitochondrial energy production
Reduced oxidative stress
Better muscle endurance and reduced fatigue
Improved recovery from cellular stress
Potential neuroprotective effects
Support for metabolic and cardiovascular health

These findings help explain the growing interest in SS-31 for longevity and wellness, but most data remain preliminary.

What SS-31 Is Not Approved For

SS-31 is not approved for general wellness, anti-aging, athletic performance, or aesthetic use. These remain off-label applications and should be approached with careful medical supervision.

Important considerations:

Human longevity data are limited
Long-term safety outside Barth syndrome is still being studied
Benefits beyond mitochondrial disorders are promising but not conclusive

We ensure that every patient understands these factors before beginning therapy.

SS-31 and the Future of Telemedicine Longevity Care

The approval of SS-31 marks a shift toward medical-grade mitochondrial therapies. It also supports the broader concept that targeting cellular energy systems may contribute to healthy aging.

For telemedicine patients, this could mean:

More access to mitochondrial support options
Better personalization in longevity care
Next-generation peptides are becoming available as research progresses

TBTotal.Health already supports mitochondrial health through NAD-based therapies, metabolic peptides, hormone optimization, and evidence-backed lifestyle strategies. SS-31 adds an option for patients who qualify.

FAQs

Can I receive SS-31 through TBTotal.Health?
Yes. We prescribe SS-31 off-label for longevity and mitochondrial support when medically appropriate.

Does SS-31 improve energy or slow aging?
Early research is promising, but large-scale human trials are needed. Benefits vary by patient.

Is SS-31 safe?
It is FDA-approved for Barth syndrome. Off-label use requires careful monitoring and informed consent.

What are alternatives for mitochondrial health?
Options include NAD support, peptide therapy, hormone optimization, sleep regulation, and strength training.

Conclusion

SS-31 is an exciting milestone in mitochondrial medicine and may represent the beginning of a new era in longevity therapeutics. At TBTotal.Health, we offer SS-31 off-label for patients seeking mitochondrial support and long-term wellness, always with full transparency and medical oversight.

If you want to explore whether SS-31 is right for you, schedule a virtual consultation with a TBTotal.Health provider today.